Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2024-09-20 00:00:00 ET · period of report 2024-09-18 · accession 0001415889-24-023777 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-09-20 | 2024-09-18 | MIRM | Heron Patrick J | Dir | P - Purchase | $37.40 | +115 | 162.3K | +0.1% | +$4,301 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-18 | P | A | 115 | $37.40 | 162,308 | I By Frazier Life Sciences X, L.P. | — | — | (F1) The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |